ReviewCurrent opinion in biotechnology2002
Antibody manufacture in transgenic animals and comparisons with other systems.
Review in Current opinion in biotechnology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Artificial intelligence advancements in monoclonal antibody development technology.Frontiers in immunology · 2026Review
- Structure of the Fab fragment of a humanized 5E5 antibody to a cancer-specific Tn-MUC1 epitope.Acta crystallographica. Section D, Structural biology · 2025Article
- Genetically modified chickens as bioreactors for protein-based drugs.Frontiers in genome editing · 2024Review
- Development of a Mucus Gland Bioreactor in LoachInternational journal of molecular sciences · 2021Article
- A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle.Scientific reports · 2018Article
- The transgenic animal platform for biopharmaceutical production.Transgenic research · 2016Review
- Expression of recombinant vaccines and antibodies in plants.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2014Review
- Use of transgenic animals in biotechnology: prospects and problems.Acta naturae · 2013Article
- Aberrant phenotypes of transgenic mice expressing dimeric human erythropoietin.Reproductive biology and endocrinology : RB&E · 2012Article
- The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.Expert opinion on drug delivery · 2010Review
- Functional recombinant human anti-HAV antibody expressed in milk of transgenic mice.Transgenic research · 2009Article
- Production of pharmaceutical proteins by transgenic animals.Comparative immunology, microbiology and infectious diseases · 2009Review
- High level expression of a functional human/mouse chimeric anti-CD20 monoclonal antibody in milk of transgenic mice.Transgenic research · 2008Article
- Cell engineering and molecular pharming for biopharmaceuticals.The open medicinal chemistry journal · 2008Article
- Preparation of recombinant vaccines.Biotechnology annual review · 2007Review
- Maternally derived recombinant human anti-hantavirus monoclonal antibodies are transferred to mouse offspring during lactation and neutralize virus in vitro.Journal of virology · 2006Article
- Production of two vaccinating recombinant rotavirus proteins in the milk of transgenic rabbits.Transgenic research · 2005Article
- Transgenic tobacco plants expressing a dimeric single-chain variable fragment (scfv) antibody against Salmonella enterica serotype Paratyphi B.Transgenic research · 2005Article
- Use of transgenic animals to improve human health and animal production.Reproduction in domestic animals = Zuchthygiene · 2005Review
- Generation and phenotypic analysis of a transgenic line of rabbits secreting active recombinant human erythropoietin in the milk.Transgenic research · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. The isolation and engineering of the corresponding genes is becoming less of a bottleneck in the process; however, the production of recombinant antibodies is itself a limiting factor and a shortage is expected in the coming years. Milk from transgenic animals appears to be one of the most attractive sources of recombinant antibodies. None of the production systems presently implemented (CHO cells, insect cells infected by baculovirus, or transgenic animals and plants) has yet been optimized. This review describes the advantages of using milk for antibody production in comparison with the other systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.